JP2004509953A5 - - Google Patents

Download PDF

Info

Publication number
JP2004509953A5
JP2004509953A5 JP2002531107A JP2002531107A JP2004509953A5 JP 2004509953 A5 JP2004509953 A5 JP 2004509953A5 JP 2002531107 A JP2002531107 A JP 2002531107A JP 2002531107 A JP2002531107 A JP 2002531107A JP 2004509953 A5 JP2004509953 A5 JP 2004509953A5
Authority
JP
Japan
Prior art keywords
methyl
morpholin
dichlorobenzyl
urea
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002531107A
Other languages
English (en)
Japanese (ja)
Other versions
JP5069392B2 (ja
JP2004509953A (ja
Filing date
Publication date
Priority claimed from GB0023973A external-priority patent/GB0023973D0/en
Priority claimed from GB0107643A external-priority patent/GB0107643D0/en
Application filed filed Critical
Priority claimed from PCT/GB2001/004350 external-priority patent/WO2002026723A1/en
Publication of JP2004509953A publication Critical patent/JP2004509953A/ja
Publication of JP2004509953A5 publication Critical patent/JP2004509953A5/ja
Application granted granted Critical
Publication of JP5069392B2 publication Critical patent/JP5069392B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002531107A 2000-09-29 2001-09-28 炎症性疾患の処置に有用な化合物 Expired - Lifetime JP5069392B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0023973A GB0023973D0 (en) 2000-09-29 2000-09-29 Therapeutically useful compounds
GB0023973.1 2000-09-29
GB0107643A GB0107643D0 (en) 2001-03-27 2001-03-27 Therapeutically useful compounds
GB0107643.9 2001-03-27
PCT/GB2001/004350 WO2002026723A1 (en) 2000-09-29 2001-09-28 Compounds useful in the treatment of inflammatory diseases

Publications (3)

Publication Number Publication Date
JP2004509953A JP2004509953A (ja) 2004-04-02
JP2004509953A5 true JP2004509953A5 (enExample) 2008-11-13
JP5069392B2 JP5069392B2 (ja) 2012-11-07

Family

ID=26245081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002531107A Expired - Lifetime JP5069392B2 (ja) 2000-09-29 2001-09-28 炎症性疾患の処置に有用な化合物

Country Status (20)

Country Link
US (1) US7157457B2 (enExample)
EP (2) EP1324991B1 (enExample)
JP (1) JP5069392B2 (enExample)
KR (1) KR20030040510A (enExample)
CN (1) CN1478084A (enExample)
AR (1) AR037080A1 (enExample)
AT (1) ATE345331T1 (enExample)
AU (1) AU2001290146A1 (enExample)
BR (1) BR0114321A (enExample)
CA (1) CA2423305A1 (enExample)
CZ (1) CZ20031194A3 (enExample)
DE (1) DE60124576T2 (enExample)
ES (1) ES2275729T3 (enExample)
HU (1) HUP0303107A2 (enExample)
IL (1) IL155092A0 (enExample)
MX (1) MXPA03002813A (enExample)
NO (1) NO20031443L (enExample)
NZ (1) NZ525055A (enExample)
PL (1) PL362984A1 (enExample)
WO (1) WO2002026723A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207450D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
CA2417826A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AR033290A1 (es) 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano
GB0207449D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207447D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
GB0207439D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207432D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207436D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0211759D0 (en) * 2002-05-22 2002-07-03 Glaxo Group Ltd Novel compounds
GB0212357D0 (en) * 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
ATE446951T1 (de) * 2003-06-10 2009-11-15 Biondi Ricardo Miguel Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung
RU2387646C2 (ru) 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
CA2579207C (en) 2004-09-08 2011-10-18 Mitsubishi Pharma Corporation Morpholine compound
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
JP2010521456A (ja) * 2007-03-13 2010-06-24 アレテ セラピューティクス, インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
JP5313881B2 (ja) 2007-04-04 2013-10-09 興和株式会社 テトラヒドロイソキノリン化合物
US8093248B2 (en) 2007-12-05 2012-01-10 Astrazeneca Ab (Publ) Compounds useful for the treatment of conditions associated with weight gain
WO2009071658A1 (en) 2007-12-05 2009-06-11 Biovitrum Ab (Publ) Piperazines as anti-obesity agents
US20140335083A1 (en) 2011-12-01 2014-11-13 Glaxo Group Limited Methods of treatment and prevention of eye diseases
FR3022142B1 (fr) 2014-06-16 2019-07-12 Universite Paul Sabatier - Toulouse Iii Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate
AR101674A1 (es) 2014-08-22 2017-01-04 Glaxosmithkline Ip Dev Ltd Uso de un compuesto tricíclico que contiene nitrógeno
WO2018134731A1 (en) 2017-01-17 2018-07-26 Glaxosmithkline Intellectual Property Development Limited Non peptidic heterobivalent molecules for treating inflammatory diseases
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
CN111269340B (zh) * 2020-03-31 2020-12-29 台州学院 一种以1-甲烷磺酰哌嗪为配体的螯合树脂及其制备方法和应用
CN120132049B (zh) * 2025-03-05 2025-08-26 西南医科大学附属口腔医院 茶多酚涂层改性的3d打印掺锶羟基磷灰石复合支架的制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
JPH04247074A (ja) * 1991-02-01 1992-09-03 Yoshitomi Pharmaceut Ind Ltd 4−モルホリノ安息香酸誘導体の製造法
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
WO1995031431A1 (en) 1994-05-18 1995-11-23 Nisshin Flour Milling Co., Ltd. Novel diaminomethylidene derivative
US5753654A (en) * 1994-05-18 1998-05-19 Nisshin Flour Milling Co., Ltd. Diaminomethylidene derivatives
HU227841B1 (en) * 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
BR9915520A (pt) * 1998-11-20 2001-07-17 Hoffmann La Roche Antagonistas receptores ccr-3 derivados de pirrolidina
AU2482100A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140833A1 (en) * 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity

Similar Documents

Publication Publication Date Title
JP2004509952A5 (enExample)
JP2002540204A5 (enExample)
JP2013506637A5 (enExample)
JP2008513500A5 (enExample)
JP2009537543A5 (enExample)
JP2006505522A5 (enExample)
JP2007516173A5 (enExample)
JP2006524686A5 (enExample)
JP2004517080A5 (enExample)
JP2009221205A5 (enExample)
CA2396824A1 (en) Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
WO2003000256A1 (de) Kombinationstherapie substituierter oxazolidinone
EP1152759A2 (en) METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
RU2002132385A (ru) Новые соединения
RU2008141510A (ru) Новые соединения
JP2002506858A (ja) Cmv感染症の治療に有用な1,3,4−チアジアゾール
JP2006503081A5 (enExample)
JP2008519761A5 (enExample)
JP2004523490A5 (enExample)
RU2012117885A (ru) 2,3,5-тризамещенные пирролы, фармацевтическая композиция и лекарственное средство (варианты) на их основе, способ получения соединений (варианты)
RU2011116232A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
JP2005514432A5 (enExample)
JP2008502614A5 (enExample)
RU2007107349A (ru) Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств
JP2005526815A5 (enExample)